- Home
- LUCY vs BMRA Comparison
LUCY vs BMRA Comparison
Compare LUCY & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | BMRA |
|---|---|---|
| Founded | 2017 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.5M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LUCY | BMRA |
|---|---|---|
| Price | $0.73 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 192.6K | 4.1K |
| Earning Date | 05-14-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,661,669.00 | ★ $5,311,000.00 |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.65 | N/A |
| 52 Week Low | $0.65 | $1.45 |
| 52 Week High | $2.24 | $3.58 |
Technical Indicators
Market Signals| Indicator | LUCY | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 43.78 |
| Support Level | $0.66 | N/A |
| Resistance Level | $1.17 | $1.75 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.02 | 56.52 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.